NCT00706966View on ClinicalTrials.gov

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

August 31, 2011

Conditions
Nonmalignant NeoplasmProstate Cancer
Interventions
DRUG

dutasteride

6 months of dutasteride 3.5 mg daily

Trial Locations (1)

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT00706966 - MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer | Biotech Hunter | Biotech Hunter